Clearly, it is (superficially at least) possible to determine via a questionnaire if a patient experiences PEM. But perhaps, in the eyes of the CDC, it would have limited value to determine PEM via a questionnaire. The CDC would be asking themselves what it would achieve in a clinical setting.
Unger's remit is for chronic fatigue. (Nearly all chronically fatigued patients satisfy the Fukuda CFS criteria.) Her remit is not for ME. So she has got to cater for all fatigued patients. If she were to introduce PEM as a diagnostic criteria in clinical settings, then this would exclude some patients, which would be problematic from her point of view, unless she can see a very good reason to do so. (She would still need to serve those patients who don't experience PEM.)
The CDC wouldn't know how to cater for the patients who don't have PEM or the patients who do have PEM, so it would probably be an unnecessary complication to separate the different patients in clinical settings, in the eyes of the CDC. (Perhaps they might see it differently if there was some easy way to make a biomedical determination for PEM in a clinical setting.)
So my (charitable) feeling is that the CDC doesn't want to use PEM as a clinical marker until PEM can be more easily determined by a blood test etc. Because they can't see any benefit from it.
I think Firestormm makes some valid points: In reality, asking a patient if they experience PEM would have very little practical value in a standard (general practitioner) clinical setting because PEM means different things to different people, and it's difficult for people (including clinicians) to understand the concept of PEM in ME if they've never experienced it. As Firestormm says, if asked, many people without ME would say that they experience PEM. So a questionnaire would not be a great method of creating well-defined subgroups. (Also, PEM is not a clear-cut or obvious phenomenon in many ME/CFS patients, even if they do experience it.)
And once a doctor has determined whether a patient has PEM, or not, then what? There are still no treatments on offer for the average patient.
So, determining PEM via a questionnaire would have some value, but limited value, in a clinical setting, in my opinion. Its biggest value would be to start to move the field forwards, by having the symptoms of ME properly recognised. So it may make a long-term difference. A step in the right direction. (We might be able to better fight the cognitive-behavioural model of illness if PEM was recognised as a prominent symptom.) However, in the UK, PEM is a requirement (via NICE - although the NICE criteria are worded ambiguously, in my opinion) and it hasn't made the slightest difference for us.
I am a strong advocate of subsetting though, and of diagnosing ME using PEM, esp in research settings.
I'm just pointing out the various flaws in the current system.
Determining PEM in a clinical setting would not be a panacea. It's made little difference, if any, in the UK. But perhaps it was a baby step forwards.
In the video that I linked to earlier, Beth Unger did emphasise the importance of subsetting (but it's never clear if she's talking about clinical or research settings), but she didn't specify that PEM should be one such subset. Perhaps, if we give her the benefit of the doubt, for the sake of discussion, she recognises the difficulties of determining the precise nature of PEM via a questionnaire, and perhaps considers that it would make little difference. And perhaps if a simple and precise test were available for PEM, she would go with it?
Anyway, she always says that she will follow her data, and she emphasises the importance of subsets. Who knows what she will conclude once she has finished her multi-site research. She says that roughly 80% of her cohort (I'm not sure if this is the multi-clinic data) experience or 'endorse' PEM. I don't agree with Mindy Katai that the other 20% are simply 'depressed', seeing as CFS is so complex and heterogeneous. Also, ME is very complex (not everyone with ME has clearly defined PEM) and ME is possibly heterogeneous.
BTW, Unger is carrying out post-exertional research. She's carrying out cognitive tests up to 48 hours after the one-day CPET test. This should give us some interesting results, if they are the right kind of cognitive tests. (I can't remember if I know what tests she is using.)
Anyway, just my two-pennies worth. Perhaps I'm being far too charitable towards the CDC. I'd certainly like to see them achieving much much more in a much shorter time frame, and I'd like to see them carrying out serious biomedical research. But I'm still hopeful that Unger is genuine about following her data, and her emphasis on the need to define subsets. I think that's what she is doing and working towards, albeit excruciatingly slowly, and without much meaningful biological data. (But I've always said that she's wiped the slate clean and is starting the CDC's program from scratch, which I think was the best approach to take. So she's got to start with clinical reports and questionnaires etc and epidemiology, rather than specific biomedical investigations.)
In the mean time, I guess we've got to look towards other research for answers.
I'd like to know where Unger stands with Lenny Jason's diagnostic criteria research. (i.e. the De-Paul symptom questionnaire whereby patients answer some simple yes/no questions for a diagnosis.)